ReviewTransboundary and emerging diseases2025
Design of Mucosal Vaccines Against Swine Enteric Coronaviruses: From Antigen Delivery to Immune Activation.
Review in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle Vaccine Based on S1 Domain of Porcine Epidemic Diarrhea Virus Elicits Protective Immune Responses in Mice and Pigs.Biomolecules · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swine enteric coronaviruses (SeCoVs) cause acute enteritis and high mortality in neonatal piglets, posing a significant threat to the swine industry. Injectable vaccines often fail to induce effective mucosal immunity, and their efficacy is further compromised by maternally derived antibodies. Oral and intranasal mucosal vaccines offer promising alternatives, enabling localized and durable protection. This review summarizes recent advances in mucosal vaccines against SeCoVs, focusing on antigen delivery platforms and mucosal immune activation. Novel antigen delivery platforms, including nanoparticles (NPs), hydrogels, engineered probiotics, recombinant viral vectors, and eukaryotic expression systems, have improved antigen stability and facilitated transport across the epithelium to mucosal inductive sites. Moreover, targeting strategies that focus on microfold cells (M cells) and dendritic cells (DCs) enhance antigen uptake and presentation. These delivery systems promote mucosal immune activation by inducing secretory IgA (sIgA), maintaining Th1/Th2 balance, and promoting the generation of T and B cells. In addition, the incorporation of adjuvants further strengthens these responses, resulting in more robust and durable protection. By synergistically integrating advanced mucosal vaccine delivery systems with rational adjuvant strategies, this review provides theoretical and practical perspectives for the development of safe, effective, and broadly protective mucosal vaccines targeting SeCoVs infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.